Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Overview
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Companies Involved in Therapeutics Development
CanBas Co Ltd
Daiichi Sankyo Co Ltd
Emcure Pharmaceuticals Ltd
F. Hoffmann-La Roche Ltd
Jiangsu Hengrui Medicine Co Ltd
Luye Pharma Group Ltd
Merck & Co Inc
Netherlands Translatiol Research Center BV
NewLink Genetics Corp
Shanghai De Novo Pharmatech Co Ltd
Syntekabio Inc
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Drug Profiles
DN-1406131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPL-1410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTI-1090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-01013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-70099 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TDO2 for End-Stage Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO and TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IDO/TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TDO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit TDO for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Dormant Products
Tryptophan 2,3 Dioxygese (Tryptamin 2,3 Dioxygese or Tryptophan Oxygese or Tryptophan Pyrrolase or Tryptophase or TDO2 or EC 1.13.11.11) - Product Development Milestones
Featured News & Press Releases
Jul 31, 2018: Approval for clinical trial for class I new chemical drug?Anti-Tumor innovative drug (LY01013) in Chi
Jun 06, 2018: De Novo Pharmatech receives approval to initiate clinical trials in Chi with IDO1/TDO2 inhibitor DN1406131
Jan 05, 2018: De Novo Pharmatech submitted the IND application of DN1406131 to FDA
Dec 04, 2017: De Novo Pharmatech submitted the IND application of DN1406131 to CFDA
Feb 10, 2015: IOmet Pharma demonstrates superior in vivo PK/PD properties in pre-clinical IDO, TDO and Dual IDO/TDO cancer immunotherapy programs
Feb 06, 2015: IOmet Pharma to present data on pre-clinical cancer immunotherapy programs at Keystone Tumor Immunology Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by CanBas Co Ltd, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by Emcure Pharmaceuticals Ltd, H1 2020
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Netherlands Translational Research Center BV, H1 2020
Pipeline by NewLink Genetics Corp, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by Syntekabio Inc, H1 2020
Dormant Projects, H1 2020